The melon in the financial circle in 2021 is a bit much, the melon passed on the 17th is a bit large, and all parties have also responded, and the fund jun will take everyone to eat tonight.
Chen Long, a former chief strategist at Zhongtai Securities, was arrested
Also involving public fund managers?
On the 17th, a chat record in the group of the financial circle swept the screen. It is mentioned that Chen Long, the former chief strategist of Zhongtai Securities, is currently missing and has been locked up by (the police), rumors that they have a small group of more than 20 people, speculating in huawei car stocks, two Huawei employees were arrested first, and the police shunten touched the melon to arrest more than 20 people. Finally, the rumor also said that the general manager of the quantitative department of the public fund, who was responsible for taking over the floating capital chips, was also investigated
What are the facts? On the evening of the 17th, Zhongtai Securities and the general manager of the original quantitative department of the public fund responded.
According to the Daily Economic News, Chen Long, a former chief strategist at Zhongtai Securities, was arrested. Some time ago, a policeman went to the company's office to find him, and then resigned.
According to the latest information from the Securities Association of China, Chen Long has registered his resignation at the China Securities Association on November 15, 2021, and officially resigned from Zhongtai Securities.
According to the public account "Crystal Ball of Cultivation Investment" of Zhongtai Strategy, Chen Long has not published a research report since November 10, 2021.
In this regard, Zhongtai Securities mentioned in its response that Chen Long had left the company on November 12 last year; in addition, the company was not aware of the information related to Chen Long on the Internet.
Another protagonist of the rumor is the former public fund manager Jin Fangyi, in response to this, he responded in the circle of friends that everything is normal in work and life, Jin Fangyi said that at present, he is in the process of entrepreneurship, planning to set up a private fund, people in Shanghai.
According to public information, Jin Fangyi is a doctor of economics, a financial risk manager, and a chartered financial analyst. From January 2011 to March 2018, he served as a quantitative senior researcher, a special account investment manager, a head of quantitative investment department and a fund manager in a joint venture fund management company in Shanghai. During his tenure as a fund manager, he was once known by the market as the "Four Kings of Quantification".
After joining another public fund in April 2018, he successively served as the head of the quantitative investment department and the director of quantitative investment. On November 20, 2021, Jin Fangyi announced his departure from office.
In this regard, the relevant fund company replied that Jin Fangyi had been out of his job for several months, and the company did not know about his personal situation. In addition, the company's quantitative investment team is currently operating normally, and the heads of departments and fund managers are performing their duties normally.
Crazy shareholders: Earned several times in Jiuan Medical
Want to donate money to listed companies
On January 17, the "demon stock" Jiuan Medical directly sealed a word board of 82.81 yuan / share, with a total market value of nearly 40 billion yuan.
Since the launch of the market on November 15 last year, in 45 trading days, the stock price of Jiuan Medical has soared from 6.9 yuan per share, an increase of more than 1100%.
On the news side, Jiuan Medical issued an announcement on November 8 that one of its new crown antigen home self-test OTC kits has obtained emergency use authorization (EUA) in the United States. According to reports, the kit can quickly determine the virus in the human nasal swab sample, 15 minutes out of the results, and can detect the Omikejung variant strain. Subsequently, Jiuan Medical claimed to have obtained a 2 billion yuan order from the United States.
After hours, Jiuan Medical issued a stock trading risk warning announcement, saying that the single-month performance of the kit product does not represent the annual performance, and the historical performance of the product does not represent the future performance, and the company believes that it is necessary to carry out risk warning again.
In the announcement, Jiuan Medical prompted investors from the aspects of the uncertainty of the development of the epidemic in the United States, the uncertain risk of market competition, the rationality risk of the valuation model, the reliability risk of information, the risk of logistics and transportation, the quality risk, and the risk of contract/order.
The company said that the company mentioned the epidemic prevention related plans issued by the US government in the previous announcement, as well as the relevant policies, procurement and distribution plans and situations regarding the new crown antigen home self-testing agent cartridge products. The relevant situations and procurement involved in the above content are not only for Jiuan Medical, please do not misunderstand the content and mistakenly infer the changes it will bring to the company's performance.
At the same time, the announcement reminds that the company previously submitted the "Proposal on the Use of Family Self-test Boxes to Achieve 1+1 Covid-1 Prevention of the New Crown epidemic in Aomi Kerong" to the Tianjin Municipal Epidemic Prevention and Control Command, and it is uncertain whether the proposal will be adopted.
In terms of stock price, Jiuan Medical said that the company's stock price is currently at a historical high, and the risk of a decline in the future is not ruled out.
The company's stock price is crazy, but the shareholders are more crazy, and some shareholders have made several times more violently, and want to reward the company's employees with money and make them work harder!
Shanxi Securities: Holding subsidiary
Lawsuits were filed over a misrepresentation dispute over LeTV Securities
On the evening of the 17th, Shanxi Securities issued an announcement that its holding subsidiary, Zhongde Securities, was sued, involving an amount of 4.571 billion yuan.
The announcement said that on January 13, Zhongde Securities received a civil complaint from the Beijing Financial Court on a dispute over securities misrepresentation liability. Shanghai Junying Asset Management Partnership (Limited Partnership) and 2,000 other plaintiffs filed a civil lawsuit with the Beijing Financial Court against 21 defendants, including LeTV (LeTV Information Technology (Beijing) Co., Ltd.), demanding that LeTV compensate for investment losses totaling 4.571 billion yuan caused by its misrepresentation behavior, and requiring the other 20 defendants to bear joint and several liability for compensation.
The defendants in the lawsuit involved a total of 14 natural persons such as LeTV and Jia Yueting, 3 securities companies such as Zhongde Securities, and 3 accounting firms.
LeTV investors believe that LeTV's misrepresentation behavior has caused damage to its rights and interests, and requires LeTV to bear civil compensation liability for misrepresentation infringement; Jia Yueting and 14 other natural persons bear joint and several liability for compensation as the person responsible for the fault of misrepresentation; and 3 securities companies and 3 accounting firms such as Zhongde Securities bear joint and several liability for failing to exercise due diligence and fail to discover LeTV's financial fraud.
The plaintiff asked leTV to pay the plaintiff a total of 4.571 billion yuan in tort damages (including investment difference losses, stamp duty, commissions, and interest) for investment losses caused by misrepresentation; ordered the other 20 defendants other than LeTV to bear joint and several liability for the plaintiff's above losses; and ordered the defendants to jointly bear all the litigation costs of the case.
Shanxi Securities said that the above case has not yet been heard and has not yet been decided; there is uncertainty about its impact on the company's profit in the current period or after the period.
Editor-in-charge: Liu Anqi | Review: Li Zhen | Director: Wan Junwei
(Source: China Fund News)